Article

Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy.

Department of Medical Oncology, Institute of Oncology, Hacettepe University, Ankara, Turkey.
Journal of Surgical Oncology (impact factor: 2.1). 02/2000; 73(1):12-6. pp.12-6
Source: PubMed

ABSTRACT Our objective was to assess the efficacy of a standard dose ifosfamide and doxorubicin containing regimen in the treatment of advanced soft tissue sarcomas. Forty consecutive patients with a median age of 35.5 years were treated. Ifosfamide was administered at a dose of 2.5 g/m(2)/day as 72-hour continuous infusion with mesna at the same dosage and schedule. Doxorubicin was given at the dose of 60 mg/m(2)/day as 2-hour infusion on day 1. Six patients had a complete response (15%), and 9 (22.5%) had a partial response, fourteen patients (35%) stable disease, and 11 (27.5%) did not respond to chemotherapy. The median duration of response was 13 and 5 months for the complete and partial responders, respectively. The median survival was 37 months. Febrile neutropenia was encountered in 9 cases (22.5%). The present ifosfamide and doxorubicin combination is a moderately effective and well-tolerable regimen in the treatment of advanced soft tissue sarcomas.

0 0
 · 
0 Bookmarks
 · 
20 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

2-hour infusion
 
5 months
 
72-hour continuous infusion
 
9 cases
 
chemotherapy
 
complete response
 
consecutive patients
 
doxorubicin combination
 
Febrile neutropenia
 
Ifosfamide
 
median age
 
median duration
 
median survival
 
partial responders
 
partial response
 
present ifosfamide
 
regimen
 
soft tissue sarcomas
 
standard dose ifosfamide
 
well-tolerable regimen
 

I Barişta